Gilead Sciences (GILD) said Tuesday that two different once-yearly formulations of lenacapavir for HIV prevention were found to be safe and well tolerated in an ongoing study.
The company said it presented the first data from its ongoing phase 1 study of the formulations at a medical conference and also published the results in The Lancet.
The data showed that the formulations reached and maintained blood levels above those associated with preventing HIV in earlier phase 3 trials that studied a twice-yearly version of lenacapavir.
The data will support the future development of once-yearly lenacapavir, for which Gilead plans to launch a phase 3 study in H2, the company said.
Gilead shares were down 2% in recent trading.
Price: 114.77, Change: -2.44, Percent Change: -2.08
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。